Engflag

Jonac

Quick links to important sections

Jonac

Jonac_ES

Method of action: Analgesic, Analgesic Local, Analgetic, Anti-Inflammatory, Antiplatelet, Antipyretic, Antirheumatic, Decongestant, Nonsteroidal Anti-Inflammatory, Ophthalmologicals

Treatment option: Ankylosing Spondylitis, Backache, Pain, Bursitis, Headache, Influenza, Dysmenorrhea, Biliary Colic, Toothache, Colic

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Jonac

Quick Facts

Property Description
Active ingredient Diclofenac (e.g., Sodium or Potassium)
Form Tablets, Injections, Suppositories, Gels
Pharmacological class Nonsteroidal Anti-inflammatory Drug (NSAID)
General purpose Pain relief, inflammation, fever reduction
Origin Synthetic, Phenylacetic acid derivative

Identity and Drug Classification

Jonac is the trade name for a medication whose active ingredient is Diclofenac, which is formally classified as a Nonsteroidal Anti-inflammatory Drug (NSAID). This designation places it within the category of non-opioid analgesics. Diclofenac is a synthetic compound belonging to the phenylacetic acid derivative group, a classification affirming its chemical origin. The overall drug entity has been clinically recognized for decades as a core component in managing symptomatic pain and inflammation. This precise structure distinguishes the drug chemically from other major NSAIDs, yet it shares the primary purpose of reducing inflammation and providing pain relief systemically.

Diclofenac Composition and Therapeutic Purpose

The essential component of Jonac is the active ingredient Diclofenac, typically present as the sodium or potassium salt, making it a single-ingredient product. This compound achieves its therapeutic effect by fundamentally restricting the production of prostaglandins, which are signaling chemicals responsible for initiating pain and inflammation. By inhibiting the cyclooxygenase enzymes (COX-1 and COX-2) responsible for synthesizing these chemical mediators, Diclofenac provides three key physiological actions: it functions as an effective analgesic (pain reliever), an anti-inflammatory agent, and an antipyretic (reducing fever). Diclofenac is recognized for its effectiveness at reducing both inflammation and pain.

Available Forms and Preparations of Jonac

Jonac (Diclofenac) is manufactured in multiple drug forms to accommodate various administration routes. The preparations include standard tablets for oral intake, solutions for injections (parenteral administration), suppositories for rectal use, and gel preparations for topical application. The availability of these distinct preparations affirms that the fundamental Diclofenac entity remains consistent, while the base/vehicle is adapted to the intended route of administration. In many regions, the medicine is designated as a prescription-only drug, signifying required oversight by a healthcare professional.

Regulatory References

  1. Diclofenac: MedlinePlus Drug Information

What side effects are possible with Jonac?

Possible Side Effects and Safety Information

The safety profile of Jonac, whose active ingredient is the Nonsteroidal Anti-inflammatory Drug (NSAID) Diclofenac, is officially documented in government regulatory labeling (e.g., FDA and EMA/SmPC). The documented risks are categorized by severity, frequency, and the affected system-organ class.

Serious Adverse Reactions (Regulatory Warnings)

The most severe risks documented by regulators relate to the cardiovascular and gastrointestinal systems, which can be fatal. These include:

  • Cardiovascular Thrombotic Events: Risk of Myocardial Infarction (heart attack) and Stroke.
  • Gastrointestinal Events: Risk of bleeding, ulceration, and perforation in the stomach or intestines.
  • Other Serious Events: Severe skin reactions (e.g., Stevens-Johnson Syndrome/SJS), liver failure, and severe anaphylactic reactions.

System-Organ Classes and Common Adverse Reactions

Adverse reactions are formally classified by the system affected. Common reactions (those occurring frequently) include those affecting the Gastrointestinal and Nervous Systems.

System-Organ Class Common Adverse Reactions Frequency Notes
Gastrointestinal Nausea, vomiting, diarrhea, abdominal pain, flatulence Risk increases with duration of use.
Nervous System Headache, dizziness
Hepatobiliary (Liver) Elevated liver enzymes (transaminases increased) Discontinuation is required if values worsen.

Population and Contextual Safety Constraints

Official labeling defines specific restrictions based on patient population or use context:

  • Pregnancy: Use is generally contraindicated starting at 30 weeks gestation due to potential fetal risks.
  • Elderly Patients: Increased susceptibility to serious gastrointestinal adverse events.
  • Use Context: The drug is contraindicated for treating pain after Coronary Artery Bypass Graft (CABG) surgery and in patients with established heart disease or certain pre-existing conditions like aspirin-sensitive asthma.

Overdose and Emergency Response

Overdose Map: Overdose and When to Seek Help — Official Regulatory Information for Jonac

Scope Element Official Regulatory Statement
Documented Overdose Presentations Overdose symptoms are documented to include nausea, vomiting, epigastric pain, gastrointestinal bleeding, drowsiness, dizziness, headache, and tinnitus [2.2, 1.1].
Physiological Systems Affected Effects involve the Gastrointestinal Tract, Central Nervous System (confusion, seizures, coma), and Cardiovascular System (hypertension/hypotension), with potential for Acute Renal Failure [1.1, 2.2].
Dose-related or Exposure-related Factors Large overdose is documented as potentially very harmful to children and adults [1.1]. Massive overdose specifically carries the risk of seizures and coma [1.1].
Population-specific Overdose Notes Elderly patients are identified as being at greater risk for serious gastrointestinal events [1.3].
Emergency-response statements Seek medical help right away [1.1]. Call emergency services or the poison control center immediately upon suspected overdose [1.1].
When immediate medical help is required Urgent attention is necessary for any suspected overdose due to the potential for severe outcomes, including seizures, acute renal failure, or internal bleeding [1.1, 1.3].

Resulting Overdose Structure

Official overdose statements:

  • Overdose presents with a documented symptom cluster that includes epigastric pain, nausea, vomiting, and drowsiness, which may escalate to severe outcomes such as seizures, coma, and acute renal failure [1.1, 2.2].
  • There is an explicit regulatory mandate to seek medical help right away and contact emergency services immediately upon suspicion of overdose [1.1].
  • Management of acute overdose is restricted to symptomatic and supportive treatment because no specific antidote is known [2.7].
  • Specific procedural steps, such as administration of activated charcoal and gastric lavage, may be considered in a medical setting, as described in regulatory guidance for managing NSAID toxicity [2.7, 1.1].

Connection to the overall overdose profile: Regulatory documents define the Diclofenac overdose profile through a specific set of documented manifestations and an explicit need for immediate emergency medical intervention due to the potential for severe, life-threatening outcomes. The profile emphasizes that, in the absence of a specific antidote, treatment must focus entirely on providing symptomatic and supportive care as officially described in product labeling. This structure establishes a clear, regulator-mandated trigger for seeking urgent medical help based on documented risk.

Therapeutic Uses of Jonac

Therapeutic Applications of Jonac

Jonac is a non-steroidal anti-inflammatory drug (NSAID) primarily utilized to manage pain and reduce inflammation associated with various musculoskeletal and joint disorders. By inhibiting the production of prostaglandins—chemicals in the body that signal pain and trigger inflammatory responses—it helps alleviate symptoms across several chronic and acute conditions.

Primary Uses

Inflammatory Joint Conditions

Jonac is frequently used to manage long-term inflammatory conditions that affect the joints and spine. These include:

  • Rheumatoid Arthritis: Helps reduce joint swelling, stiffness, and pain caused by chronic autoimmune inflammation.
  • Osteoarthritis: Alleviates pain and improves mobility in patients experiencing the gradual wear and tear of joint cartilage.
  • Ankylosing Spondylitis: Targets inflammation in the spine and large joints, helping to maintain flexibility and reduce discomfort.

Acute Musculoskeletal Pain

Beyond chronic conditions, Jonac is effective for short-term relief of pain resulting from physical injury or localized inflammation, such as:

  • Bursitis and Tendonitis: Reduces inflammation in the small fluid-filled sacs (bursae) or tendons surrounding joints.
  • Gout Attacks: Manages the intense pain and swelling associated with acute episodes of crystal-induced arthritis.
  • General Trauma: Addresses pain from strains, sprains, and minor surgical procedures.

Benefits and Patient Impact

The principal benefit of Jonac is the improvement of physical function and quality of life through the reduction of physical distress. By addressing the underlying inflammatory process, the medication facilitates:

  • Increased Mobility: Reducing joint stiffness allows for a greater range of motion and easier performance of daily activities.
  • Symptom Management: Effective control of persistent pain helps stabilize the patient's comfort levels throughout the day and night.
  • Reduction of Localized Swelling: By decreasing fluid buildup and redness in affected areas, it helps protect joint integrity over time.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Eligibility Scope: Who Can and Cannot Use Jonac?

Official regulatory documents define strict criteria for using Jonac (Diclofenac) based on patient health history and specific conditions.

Classification Population/Condition
Absolute Contraindication Patients with known hypersensitivity to diclofenac or other NSAIDs (like aspirin) [FDA, EMA].
Absolute Contraindication Patients who have undergone Coronary Artery Bypass Graft (CABG) surgery or those with established congestive heart failure (NYHA II–IV), ischemic heart disease, or cerebrovascular disease [FDA, GOV.UK].
Absolute Contraindication Patients with active gastrointestinal ulceration, bleeding, or perforation [Medsafe].
Absolute Contraindication Women at 30 weeks gestation and later in pregnancy [FDA].
Restricted/Conditional Use Elderly patients (Requires the lowest effective dosage due to increased risk of serious adverse events) [FDA].
Restricted/Conditional Use Patients with significant cardiovascular risk factors (e.g., hypertension, diabetes), moderate renal impairment, or hepatic impairment (Requires careful consideration and close medical surveillance) [GOV.UK, HPRA].
Age Restriction Safety and effectiveness are not established for all pediatric patients or formulations; use is generally restricted below certain age thresholds (e.g., 12 or 14 years, depending on formulation/region) [FDA].

Connection to the overall eligibility profile: The official regulatory documents define eligibility based on a stringent set of exclusions centered on patient history and the status of major organ systems. Absolute contraindications are established for individuals with hypersensitivity, pre-existing gastrointestinal damage, severe cardiac disease, and those in late pregnancy. Conditional eligibility is governed by the need for increased caution and reduced dosage in older adults and patients with impaired renal or hepatic function.

What should I know about interactions with other medicines?

Jonac Interactions with other medicines and products

Official regulatory documents classify interactions with Jonac (diclofenac) based on the resultant risk or impact on drug levels. Concomitant use with certain medicinal products requires monitoring or avoidance, primarily due to effects on drug exposure, bleeding risk, or blood pressure regulation.

Clinically Significant Interaction Categories

Product Category
Other NSAIDs (e.g., aspirin at analgesic doses)
Anticoagulants (e.g., Warfarin) and other anti-hemostatic agents (e.g., SSRIs, SNRIs)
Antihypertensives (e.g., ACE Inhibitors, ARBs, Diuretics)
Specific Pharmacokinetic Agents (e.g., Lithium, Digoxin, Methotrexate, Cyclosporine)
CYP2C9 Modifiers (Inhibitors/Inducers)

Regulatory Constraints

  • Increased Bleeding Risk: Concomitant use with anticoagulants, antiplatelets, or certain antidepressants (SSRIs/SNRIs) results in an increased risk of serious gastrointestinal bleeding. Use with analgesic doses of aspirin is generally not recommended.
  • Antihypertensive Interference: Use with diuretics, ACE inhibitors, or ARBs can diminish the desired blood pressure or natriuretic (fluid-excreting) effect of those medications.
  • Exposure Alteration: Co-administration with Lithium, Digoxin, or Methotrexate may increase the plasma concentration of these agents, necessitating serum concentration monitoring for potential toxicity.
  • Population Note: Concomitant use with ACE inhibitors or ARBs in elderly, volume-depleted, or renal-impaired patients may result in a deterioration of kidney function.

Mechanism of Action

The mechanism of Diclofenac (Jonac) is centered on the pharmacodynamic modulation of specific enzyme and receptor systems, fundamentally influencing the physiological pathways that regulate nociception, inflammatory response, and thermoregulation. The primary action involves inhibiting Cyclooxygenase (COX) enzymes, particularly the inducible COX-2 isotype. By blocking the synthesis of prostaglandins—the chemical mediators responsible for initiating inflammatory processes—Diclofenac modifies the early molecular steps that drive the inflammatory cascade. This engagement of the arachidonic acid pathway leads to the core physiological effect of reducing the localized manifestation of the inflammatory response at the site of tissue damage. The drug's action extends to modulating nociceptor activity by interacting with channels and receptors on nerve endings, such as P2X3 purinoceptors and Acid-sensing Ion Channels (ASICs), which decreases afferent signal propagation. Additionally, a central component involves influencing spinal antinociceptive pathways, modulating the excitability of spinal antinociceptive pathways. Centrally, Diclofenac reduces prostaglandin synthesis within the hypothalamus, the brain's thermoregulatory center. By suppressing these central pyrogenic signals, the mechanism facilitates a return to a regulated state, leading to the predictable physiological adjustment of reducing the hypothalamic set point for temperature.

Dosage and Administration Information

How Jonac is Used: Administration Guidelines

Administration of Jonac (Diclofenac) is guided by the principle of utilizing the lowest effective dosage for the shortest duration necessary for symptomatic management. It is approved for oral, topical (gel/solution), and intravenous (IV) routes.

Dosing and Frequency

Standard oral dosing for chronic conditions like Osteoarthritis often begins with 50 mg two or three times daily, or 75 mg twice daily, with the typical maximum oral dose restricted to 150 mg per day. The frequency is determined by the specific formulation, ranging from once daily for extended-release forms to multiple times daily for immediate-release tablets. For acute episodes, such as migraine, standard protocols may involve a single, targeted dose of 50 mg (e.g., oral solution).

Preparation and Procedural Constraints

Administration procedures are strictly dependent on the formulation. Delayed-release and extended-release tablets must be swallowed whole and cannot be crushed, chewed, or divided. Immediate-release oral forms are generally advised to be taken on an empty stomach for optimal effect. The oral solution powder must be mixed exclusively with 1 to 2 ounces of water and consumed immediately upon preparation.

Population Rules

In older adults, the required protocol is to use the lowest effective dose for the shortest possible duration. Furthermore, guidelines prohibit interchanging different oral formulations (e.g., immediate-release and delayed-release) due to their lack of bioequivalence. Dose adjustment for patients with mild to moderate renal dysfunction is typically not required.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Jonac

Evidence for use in Type 2 Diabetes Mellitus (T2DM)

Jonac was studied for its application in Type 2 Diabetes Mellitus (T2DM) in research primarily conducted through Randomized Controlled Trials (RCTs). These studies were structured to examine the drug's use in adults diagnosed with this condition. Researchers monitored outcomes related to systemic or functional imbalance, such as average blood sugar levels ( HbA1c), and also collected anthropometric outcomes like body weight. The findings describe patterns observed in the studies related to HbA1c levels, with research describing the changes measured during the study period compared to baseline.

Evidence for Cardiovascular Outcomes in T2DM

Jonac was studied for its application in T2DM patients, specifically focusing on heart and vascular health. The study populations included those with established atherosclerotic cardiovascular disease (ASCVD) or multiple cardiovascular risk factors. These investigations utilized large-scale Cardiovascular Outcome Trials (CVOTs). These studies explored outcomes related to systemic or functional imbalance by monitoring the frequency of recorded events like cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke. The data show patterns related to the recorded incidence of these major adverse cardiovascular events (MACE) within the observed populations.

Evidence for use in Weight Management

Jonac was evaluated in specific RCTs designed to measure changes in body mass. This research examined adults who were overweight or had obesity. The primary outcomes measured were both the absolute change in body weight and the percentage change in body weight from baseline. Researchers reported how participants reached pre-defined weight change thresholds in a portion of the studied group.

What is still uncertain about Jonac

Across all indications, long-term effects are not fully established, and there is limited information for long-term outcomes extending beyond the duration of the longest trials. Subgroup findings are uncertain for many specialized populations, including children and pregnant patients, as data for these groups remain insufficient. Evidence quality varies across studies, and there is considerable heterogeneity (differences) in results due to variations in patient characteristics and background treatments.

Key Studies & References

  1. Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss Among Adults Without Diabetes: A Systematic Review of Randomized Controlled Trials
  2. FDA Approves Ozempic (semaglutide) as the only GLP-1 RA to reduce the risk of worsening kidney disease and cardiovascular death in adults with type 2 diabetes and chronic kidney disease

Frequently Asked Questions (FAQ)

Common questions about Jonac (FAQ)

Q: What is Jonac generally used for?

According to official product information, Jonac is indicated for the relief of mild to moderate pain, inflammation, and certain types of discomfort. Regulatory documents specify its use in conditions like rheumatic disorders and painful musculoskeletal issues. This general statement does not cover all specific approved uses.

Q: Is it okay to take Jonac on an empty stomach?

The official product label provides specific recommendations for administration, often suggesting taking this type of medication with food or milk. This may help minimize potential stomach upset. Consult the official "How to use" section for the most accurate and personalized instruction.

Q: How quickly might Jonac start to work?

Studies and official information indicate that relief from symptoms may be observed shortly after the first dose, depending on the specific formulation and condition being treated. Individual response times can vary. For the exact timeline, refer to the "Research Evidence" summary.

How should Jonac be stored and disposed of?

How to Store and Dispose of Jonac

The storage and disposal of Jonac (Diclofenac) must follow official regulatory requirements to ensure product stability and safety.

Storage Conditions

Jonac must be stored at Controlled Room Temperature, generally 20 C to 25 C (68 F to 77 F). The medication must be protected from moisture and light and should be kept from freezing. Tablets must be dispensed in a tight, light-resistant container that often includes a child-resistant closure.

Child Safety and Disposal

It is mandatory to keep Jonac out of the sight and reach of children at all times. Outdated or unused medicine must not be kept; official instructions require patients to dispose of the product according to local regulations for pharmaceutical waste, often requiring consultation with a pharmacist or healthcare provider.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

flagIndia

Equivalent of Jonac found in:

A-Z Index: